<DOC>
	<DOCNO>NCT02079896</DOCNO>
	<brief_summary>Dialysis patient regularly suffer anemia may cause various contribute factor , alone combination , include blood loss , low erythropoietin iron sequestration . In patient , anemia responsive treatment erythropoietin erythropoiesis stimulate agent ( ESA ) alone combination intravenous ( i.v . ) iron . In 10 % patient however , anaemia respond appropriately standard treatment high high dos ESA i.v . iron use maintain acceptable hemoglobin concentration . In patient , hepcidin identify causative factor lead anemia chronic disease functional iron deficiency ESA-hyporesponsiveness . The Spiegelmer lexaptepid pegol ( NOX-H94 ) offer hepcidin-specific approach treatment anemia chronic disease . The safety activity lexaptepid pegol support data healthy subject patient multiple myeloma lymphoma . The present study dialysis patient functional iron deficiency ESA-hyporesponsiveness conduct demonstrate safety lexaptepid pegol population , investigate pharmacokinetic ( PK ) pharmacodynamic ( PD ) profile efficacy increase haemoglobin ( Hb ) dialysis patient .</brief_summary>
	<brief_title>Lexaptepid Pegol ( NOX-H94 ) ESA-hyporesponsive Anemia Dialysis Patients</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<criteria>End stage renal disease treat maintenance hemodialysis . Anemia : Hb 7 11 g/dL . Functional iron deficiency : Transferrin saturation &lt; 30 % , Ferritin ≥300 ng/mL . ESAhyporesponsiveness erythropoietin dose ≥12,000 IU/ week . Treatment darbepoetin methoxypolyethyleneglycolepoetin . Uncontrolled / unstable cardiovascular , peripheral arterial cerebrovascular disease . Congestive heart failure : New York Heart Association Class III IV . Unstable angina , myocardial infarction , percutaneous transluminal coronary angioplasty/stents , coronary artery bypass graft &lt; 3 month prior screen . Any medical condition require change treatment within 4 week prior screen make study participation unadvisable . History clinically relevant hemolysis and/or blood loss . AST , ALT , bilirubin ≥2.0 time upper limit normal . Known bone marrow fibrosis . Treatment i.v . iron &lt; 4 week prior screen screen period change erythropoietin dose last month . Any acute chronic infection , viral bacterial within 4 week prior screen screen period consider systemic infection .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Dialysis</keyword>
</DOC>